No difference in the protein content of myostatin, MuRF-1, MAFbx and LC3A/B was detected between myotubes treated with serum from NAFLD and ESLD patients without the presence of leucine. Here, FBXO32 is linked to metabolic dysfunction-associated steatotic liver disease.